about
Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneLong-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.Active idiotypic vaccination versus control immunotherapy for follicular lymphomaIntravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature.The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.Hodgkin's disease: prognostic factors and short-course regimens.Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyPhase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Antibodies for the treatment of diffuse large cell lymphoma.Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.The role of body mass index in survival outcome for lymphoma patients: US intergroup experienceRandomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialOutcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialIbrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaTherapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.Therapy of relapsed Hodgkin lymphoma.Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraUS Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.Modern treatment of Hodgkin lymphoma.
P50
Q28287838-D0D9B0A8-C253-462B-B4C7-846732D0395BQ28553703-1DC84FEF-304B-4C10-9DEC-484403D065A0Q30252598-C4AF87E0-6C0C-4BCE-AD1E-9B004B9AF3A6Q33342594-2E36B993-4B12-4DA9-BF8D-24F9F1270950Q33361773-630A0A42-CD6D-45D1-A216-8883F1EA96D0Q33363034-BE6ADC37-258D-47BB-ADC8-CDC04FF01710Q33374864-6D5FDB05-DB8E-463F-A316-DA871F138A38Q33375800-5C780584-34DA-40D2-85E4-809F76828A02Q33413598-AA933AB5-9EFA-4199-B71B-F20FF4C89DECQ33415880-AD80FC34-39B9-430C-8129-B1C8FFFDFF6BQ33423638-662FD811-9675-4F33-8761-D2DEF5AA1972Q33426847-9155B410-9399-4B61-92B8-94F314CED9D8Q33428297-29A7ED0C-2C75-4BA5-B2D5-07530BCC5B24Q33442575-F8E9E30D-1CDC-42B1-A0C5-6547DA691D9DQ33442755-3018D008-3334-406A-AAAA-A315928B27FDQ33606294-058D4104-7A96-402C-BEE6-4382FA1F9723Q33691505-3D1FEACC-1592-4F15-9A99-29E9DC11A0F4Q33718899-EA761D00-CF54-41F2-BC7F-2E6ACD861AF1Q33877409-1BEC1482-508A-4CF5-85E1-DBF5C9DFA4E7Q33909887-E3111532-B738-48CD-B965-39D20A26E9ACQ34107868-BD90C72A-06CD-44AF-8542-E697872C2A02Q34226010-74F76A19-7060-4563-BBFD-1A9922CB82F3Q34339088-171B298E-216B-4347-8FBE-FF50EC676CE9Q34645722-D137B2F9-D116-4802-83F2-7618CFF64097Q35206351-74B2FF40-EB96-4DD2-896E-7E1AB742E259Q35586880-0278CBF8-0A50-4627-B9C7-8961F32DA245Q35611950-DB5EADEE-887E-46FE-A0A4-A4A587C1461AQ35671369-E043C9E5-81D6-46A6-8291-4B26E6425989Q35979057-20900C2C-F737-4A0B-B10D-827012F5499FQ36160955-446198B5-AF01-4DB4-8504-7720D7A34553Q36211619-1ED7CFC6-F0D1-4FCD-8692-CA159FBC64A0Q36333526-C6D146EA-9B15-427D-85C7-BE4FFD6C52BAQ36490049-9D8D12D3-07C0-4E86-B7DC-6037E2B7741BQ36498968-F5E23135-BE35-49A6-A579-DDA9A63ADDD6Q36787729-0EF6F6BA-10FF-436D-9833-629EF8FE2A76Q36814594-668ED894-80E4-4336-AF8A-6012917C4023Q36904013-FE87EB2A-6586-4F61-8A56-F4A7EBE8DA31Q36939926-9628C1E0-5055-43A6-AAF6-45DABF1800C5Q37138259-2DB5A1B8-630C-4ADB-AFD6-99B5D87FE667Q37184370-085794BD-642E-45B8-8080-DF9F99A0C3CF
P50
description
Forscher
@de
chercheur
@fr
hulumtuese
@sq
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Nancy L Bartlett
@ast
Nancy L Bartlett
@en
Nancy L Bartlett
@es
Nancy L Bartlett
@nl
type
label
Nancy L Bartlett
@ast
Nancy L Bartlett
@en
Nancy L Bartlett
@es
Nancy L Bartlett
@nl
prefLabel
Nancy L Bartlett
@ast
Nancy L Bartlett
@en
Nancy L Bartlett
@es
Nancy L Bartlett
@nl
P21
P31
P3762
P496
0000-0001-8470-394X